Professor and Chair of the Department of Hematology and Medical Oncology at Emory University, Fadlo Khouri speaks at a symposium on tumor profiling at Le Vendome in Beirut, Wednesday, June 18, 2014. (The Daily Star/Mahmoud Kheir)
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Cancer patients in Lebanon will soon be able to benefit from a new genetic test that helps to identify the best course of treatment more precisely, efficiently and cheaply, experts announced this week.The test is especially beneficial for patients whose cancer is in the advanced stages, Khuri said.So patients who suffer from cancers that are rare, aggressive or metastatic – have moved from one place in the body to another – are all ideal candidates for the tumor-profiling test.Patients with a survival rate of over 90 percent do not need to take the test.
Iraqi Christians find little help
Caged birds: Songs of freedom, dirges of oppression
Hanafi reflects on lack of Arab contribution in social sciences
FOLLOW THIS ARTICLE